Xponance Inc. Increases Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Xponance Inc. boosted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 7.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,773 shares of the company’s stock after buying an additional 968 shares during the quarter. Xponance Inc.’s holdings in Apellis Pharmaceuticals were worth $528,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in APLS. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Apellis Pharmaceuticals during the 1st quarter valued at approximately $3,218,000. Bellevue Group AG raised its position in Apellis Pharmaceuticals by 3.5% during the fourth quarter. Bellevue Group AG now owns 821,800 shares of the company’s stock worth $49,193,000 after acquiring an additional 27,959 shares during the period. Edgestream Partners L.P. purchased a new position in Apellis Pharmaceuticals during the first quarter valued at $942,000. Altitude Crest Partners Inc. acquired a new stake in shares of Apellis Pharmaceuticals in the fourth quarter valued at about $9,111,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Apellis Pharmaceuticals by 38.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock worth $147,277,000 after purchasing an additional 677,098 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now owns 100,000 shares of the company’s stock, valued at $3,623,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on APLS. HC Wainwright decreased their price target on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating on the stock in a research note on Friday, August 2nd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $80.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, July 31st. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price objective on shares of Apellis Pharmaceuticals in a research note on Friday, September 20th. Wells Fargo & Company lowered their target price on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Tuesday, September 24th. Finally, Robert W. Baird reduced their target price on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a research report on Monday, September 23rd. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $70.20.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $28.84 on Tuesday. The company’s 50-day moving average is $37.01 and its two-hundred day moving average is $42.49. Apellis Pharmaceuticals, Inc. has a 1-year low of $28.33 and a 1-year high of $73.80. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. The firm has a market capitalization of $3.50 billion, a price-to-earnings ratio of -8.34 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The company had revenue of $199.70 million during the quarter, compared to analyst estimates of $190.89 million. During the same period in the prior year, the business posted ($1.02) earnings per share. The firm’s revenue for the quarter was up 110.2% compared to the same quarter last year. Analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.34 EPS for the current year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).